Constellation Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical entity, dedicated to identifying and advancing novel therapeutic solutions. Its core mission is to address critical unmet medical requirements for patients battling cancers characterized by aberrant gene expression or drug resistance. The company's pipeline features several key candidates: CPI-0610 is undergoing Phase II clinical assessment for myelofibrosis, administered in combination with ruxolitinib. Another significant compound, CPI-1205, is currently in Phase Ib/II clinical trials, targeting metastatic castration-resistant prostate cancer when used alongside androgen receptor signaling inhibitors. Beyond these, Constellation is also progressing CPI-0209 through the Phase I dose-escalation segment of its Phase I/II clinical trial for solid tumors. Established in 2008, the firm was formerly known as Epigenetix, Inc. before rebranding in March of that year to its present name. Constellation Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.